Abbott Pinning Tricor Growth On Improved Formulation, Combination Use
This article was originally published in The Pink Sheet Daily
Executive Summary
Company expects the lipid-lowering agent to eventually reach $1 bil. in revenue, almost double the U.S. sales level in 2003. Abbott points to "four strong formulation patents" on the fenofibrate tablet formulation which, it believes, will help keep generics at bay.
You may also be interested in...
Court Will Examine Antitrust Implications Of Abbott Formulation Change
Judge denies Abbott’s consolidated motion for dismissal in Tricor case.
Court Will Examine Antitrust Implications Of Abbott Formulation Change
Judge denies Abbott’s consolidated motion for dismissal in Tricor case.
Tricor/Statin Combo Could Have Edge Over Pfizer's Lipitor/Torcetrapib, Abbott Says
Fenofibrate/statin combination also has advantage of known safety profile for both components, the company maintains.